Tag: Pharma & Biotech
Dramatic growth in the immuno-oncology field suggests a paradigm shift across oncology in the coming years. This evolution will impact decision-making for all novel oncology assets, and in particular for non-IO therapies. To compete in this future environment and ensure success within the future standard of care, cancer drug developers must think strategically regarding enduring white space opportunities and how to best position novel agents to capture these opportunities.
In this article published in In Vivo, we review key strategic considerations across clinical development, market access, and post-launch commercialization that will be important for current and future oncology drug development.
By providing my email address, I agree to ClearView's online policies